Clinical Trial Search

Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097

Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours

Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants

Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87

Primary: Number of Participants Retained in Treatment — 13; 13 participants — p=0.77

Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale

Primary: Number of Participants Retained in Study — 18 participants

Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 participants

Primary: Subjective Opioid Withdrawal Total Adjective Score — 5.8; 7.7; 6.9 units on a scale

Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores

Primary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants

Primary: Treatment Engagement — 23; 11; 6 participants — p=<0.001

Primary: Drug Self-administration Breakpoint — 347; 363; 1472; 43 Clicks on a computer mouse

Primary: Retention in Treatment — 7; 5; 6 participants — p=0.32

Primary: Abuse Liability Proxy — 0.197; 0.483; 0.159; 7.678 units on a scale (points 0-100) — p=<.05

Primary: Mean Change in Subcortical Brain Structure Volume — 0.054; 0.74; 0.27; 0.48 cubic centimeters — p=>0.05

Primary: Proportion of Patients Successfully Inducted to Receive Naltrexone Injection — 12; 7 Participants

Primary: Opioid Craving — 21.6; 22.4; 23.3; 23.4 score on a scale

Primary: Illicit-positive Urines During Treatment and Follow-up — 0; 0; 1; 1 Participants

Primary: Detoxification Phase: Changes in Percent of Illicit Opioid-positive Urine Samples Over Time — 35.0; 41.6 percentage of urine positive samples — p=0.77

Primary: Number of Patients Reporting Treatment-Emergent Adverse Events — 20; 21 participants

Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale

Primary: The Primary Endpoint Will be Safety and Tolerability of CBD. — 13; 4 participants

Primary: Brain Regions With Increases or Decreases in Amplitude of Low Frequency Fluctuations (ALFF) Associated With Ondansetron Administration — 0.519; 0.562; 0.478; 0.486…

Primary: Self-Administration of Drug Units Earned — 0.00; 3.83; 3.67; 0.00 Number of drug units

Primary: Change in Clinical Institute Withdrawal Assessment for Alcohol (CIWA) Score — -2.76; 1.01 units on a scale

Primary: Change in Self-reported Cue-elicited Drug Craving as Measured by Visual Analog Scale (VAS) — -5.00; -13.34 score on a scale

Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants

Primary: Drug Cue+ Stressor Induced Craving — 1.52; 1; 1.72; 1.96 units on a scale

Primary: OOWS Score — 3.5; 1.0; 0 units on a scale (OOWS Scale) — p=0.0001